

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL


USAN (HI-240) OLPASIRAN
PRONUNCIATION ol" pa sir' an
THERAPEUTIC CLAIM Treatment of atherosclerosis

CHEMICAL NAMES

1. RNA, (Cm-sp-Am-Gm-Cm-Cm-Cm-Cm-Um-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)A-(2'-deoxy-2'-fluoro)U-Um-Gm-Um-Um-Am-Um-Am-Cm-Gm-(3'→3')-sp-dA), 5'-[O-[(23S,28S)-37-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-23,28-bis[[[2-[2-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]ethoxy]ethyl]amino]carbonyl]-21,26,31-trioxo-3,6,9,12,15,18,35-heptaoxa-22,27,32-triazaheptatriacont-1-yl] hydrogen phosphorothioate], complex with RNA (Um-sp-(2'-deoxy-2'-fluoro)U-Am-(2'-deoxy-2'-fluoro)U-Am-Am-Cm-Am-Am-(2'-deoxy-2'-fluoro)U-Am-(2'-deoxy-2'-fluoro)A-Gm-(2'-deoxy-2'-fluoro)G-Gm-(2'-deoxy-2'-fluoro)G-Cm-sp-(2'-deoxy-2'-fluoro)U-sp-Gm) (CAS)
2. *All-P-ambo-5'-O-[(25S,30S)-39-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]-25,30-bis[(2-{2-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]ethoxy}ethyl)carbamoyl]-1,23,28,33-tetraoxo-1-sulfanyl-2,5,8,11,14,17,20,37-octaoxa-24,29,34-triaza-1λ⁵-phosphanonatriacontan-1-yl]-2'-O-methyl-P-thiocytidylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-deoxy-2'-fluoroadenylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-O-methyl-P-thioguanlylyl-(3'→3')-2'-deoxyadenosine duplex with *all-P-ambo-2'-O-methyl-P-thioguanlylyl-(5'→3')-2'-deoxy-2'-fluoro-P-thiouridylyl-(5'→3')-2'-O-methylcytidylyl-(5'→3')-2'-deoxy-2'-fluoroguanlylyl-(5'→3')-2'-O-methylguanylyl-(5'→3')-2'-deoxy-2'-fluoroguanlylyl-(5'→3')-2'-O-methylguanylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-O-methyladenylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-O-methyladenylyl-(5'→3')-2'-O-methyladenylyl-(5'→3')-2'-O-methylcytidylyl-(5'→3')-2'-O-methyladenylyl-(5'→3')-2'-O-methyladenylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-O-methyladenylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-O-methyl-P-thioguanlylyl-(5'→3')-2'-deoxy-2'-fluoro-P-thiocytidylyl-(5'→3')-2'-O-methyluridine* (WHO INN proposed List #123)*

STRUCTURAL FORMULA

SEQ 1 cagcccccuaa uuguuauacg a
SEQ 1 ucguauaaca auaaggggcu g (CAS)





Legend

X : 2'-deoxy-2'-fluoro

X : 2'-O-methyl

=Ad : -(3'->3')-sp-dA



(Structure above from WHO INN proposed List #122, recommended INN list #84)

MOLECULAR FORMULA C₄₉₀H₆₅₂F₁₁N₁₆₄O₃₀₆P₄₁S₇

MOLECULAR WEIGHT 15438.7 Da

TRADEMARK None as of yet

SPONSOR Amgen Inc.

CODE DESIGNATIONS AMG 890

CAS REGISTRY NUMBER 2225856-03-9

UNII 8M4GC1EOB4

WHO NUMBER 11099

SCS